Lastly, the fifth cluster consisted of 3 controls,1 MS patient, and 1 myasthenia gravis patient (0-250 mlU/mL of SARS-CoV-2 IFN-γ and 400-650 AU/mL SARS-CoV-2 IgG). This evidence concerns the gene IFNG and myeloid sarcoma.